In 1990, a US government lab cloned the gene for the cannabinoid receptor (CB1), revealing it to be a G-protein-coupled receptor and the most abundant receptor of its kind in the mammalian brain — explaining why cannabis affects so many bodily functions.
Anyone wanting to understand why cannabis affects so many bodily functions, how tolerance develops at the molecular level, or the science behind cannabinoid receptor recovery during tolerance breaks.
Most abundantG-protein-coupled receptor in the mammalian brain — denser than serotonin, dopamine, or opioid receptors, explaining why cannabis affects memory, mood, pain, appetite, and coordination simultaneously
The Backstory
By 1988, the evidence was overwhelming. Cannabinoids didn't just dissolve into cell membranes and cause chaos. They bound something specific — something saturable, stereoselective, coupled to G-proteins. A receptor. But nobody had the gene. Nobody could say what the protein looked like, how many amino acids it had, or where exactly its messenger RNA was expressed.
In Bethesda, Maryland, a laboratory at the National Institute of Mental Health was systematically cloning orphan receptors from rat brain tissue — receptors whose genes could be identified but whose function was unknown. One of them was about to become the most important receptor in cannabis science.
The Evidence Before the Gene
The pharmacological case for a cannabinoid receptor had been building for years.
In 1988, Allyn Howlett and William Devane at St. Louis University demonstrated that a synthetic cannabinoid (CP55940, developed by Pfizer) bound to specific sites in rat brain membranes with extraordinary precision. The binding was saturable — there were a finite number of sites, not infinite membrane surface. It was stereoselective — one mirror-image form of the molecule bound while its twin did not. And it was sensitive to pertussis toxin, which meant the binding site was coupled to Gi/o proteins — the same signaling family used by opioid and serotonin receptors.
This wasn't membrane disruption. This was a receptor.
In 1989, Miles Herkenham at the NIMH mapped where these binding sites were densest using autoradiography — essentially, radioactive cannabinoids photographing their own binding pattern across sliced rat brains. The map showed dense binding in the hippocampus, cerebellum, basal ganglia, and cortex. The shadow of the receptor was visible. Its gene was not.
Fishing for Orphans
Tom Bonner's lab at the NIMH was in the business of finding new G-protein-coupled receptors. GPCRs are the largest family of cell-surface receptors in the human genome — over 800 members — and in the late 1980s, many were still uncharacterized. Bonner's team used a systematic approach: screen rat brain cDNA libraries for sequences with homology to known GPCRs, clone the candidates, express them in cell lines, and figure out what they respond to.
Process
How the CB1 Gene Was Found
Screen a cDNA library
Rat brain messenger RNA was converted to complementary DNA (cDNA) and screened for sequences resembling known G-protein-coupled receptors.
Clone the orphan
A novel GPCR sequence was identified — seven transmembrane domains, the hallmark of the GPCR family — but its ligand was unknown.
Express in cells
The cloned gene was inserted into cultured cells, forcing them to produce the receptor protein on their surface.
Test against cannabinoids
The cells were exposed to a panel of cannabinoid compounds. The receptor inhibited adenylate cyclase in a dose-dependent, stereoselective, pertussis toxin-sensitive manner — matching the pharmacological profile Howlett had described.
Map the mRNA
In situ hybridization revealed that the receptor's messenger RNA was expressed in exactly the brain regions where Herkenham had mapped cannabinoid binding sites. The orphan had found its family.
Matsuda et al. (1990), Nature 346:561-564
Lisa Matsuda, the first author, performed the core cloning and expression work. The key test was pharmacological: when the expressed receptor was exposed to psychoactive cannabinoids like THC, it inhibited adenylate cyclase powerfully. When exposed to non-psychoactive cannabinoids, it barely responded. The receptor was selective. It was specific. It was the molecular target through which cannabis works.
472 Amino Acids
The paper was published August 9, 1990, in Nature — one of the most prestigious scientific journals in the world. Four pages.
472
amino acids make up the human CB1 receptor protein — a seven-transmembrane-domain G-protein-coupled receptor that turned out to be the most abundant GPCR in the mammalian brain.
By comparison, the mu-opioid receptor (which mediates morphine's effects) is 400 amino acids and far less abundant.
Matsuda et al. (1990), Nature; Zou & Kumar (2018), PMC5877694
What the paper reported:
- A novel GPCR, 7 transmembrane domains, coupled to Gi/o proteins
- Inhibits adenylate cyclase dose-dependently, stereoselectively
- Responds preferentially to psychoactive cannabinoids
- mRNA localized to hippocampus, cerebellum, basal ganglia, cortex — matching known binding sites
- 97-99% amino acid identity between rat, mouse, and human versions — this receptor is ancient and conserved
The gene was designated CNR1. The receptor became known as CB1.
The Most Abundant Receptor You've Never Heard Of
The real surprise came from distribution studies that followed. CB1 wasn't just present in the brain — it was dominant.
Results
CB1 Receptor Density Across Brain Regions
Herkenham et al. (1990); Mackie (2005); Zou & Kumar (2018)
CB1 is the most abundant G-protein-coupled receptor in the mammalian brain — denser than receptors for serotonin, dopamine, opioids, or any other neurotransmitter system. This single fact explains the breadth of cannabis effects:
- Hippocampus (high density) → THC impairs short-term memory
- Cerebellum (high density) → THC disrupts coordination and balance
- Basal ganglia (high density) → THC alters movement and reward processing
- Cortex (moderate density) → THC changes perception and cognition
- Amygdala (moderate density) → THC can trigger anxiety or paranoia
- Hypothalamus (moderate density) → THC stimulates appetite (the munchies)
- Brainstem (very low density) → Cannabis doesn't stop breathing or heartbeat
That last point is clinically significant. Opioid receptors are dense in the brainstem, which is why opioid overdoses cause fatal respiratory depression. CB1 receptors are sparse there, which is a major reason cannabis has never caused a confirmed overdose death from respiratory failure.
Not Just a "Marijuana Receptor"
Myth vs. Reality
CB1 is the 'marijuana receptor' — it exists because of the cannabis plant.
CB1 evolved hundreds of millions of years before humans encountered cannabis. It exists for the endocannabinoid system — the body's own cannabinoid signaling network. THC works because it hijacks a receptor the brain built for its own molecules.
The Evidence
CB1 is found in virtually all vertebrates, including fish and reptiles that have no evolutionary exposure to cannabis. The endocannabinoid system predates the cannabis plant by hundreds of millions of years. The receptor's endogenous ligands — anandamide and 2-AG — were not discovered until 1992 and 1995, after the receptor itself was cloned.
McPartland et al. (2006); Zou & Kumar (2018), PMC5877694
And CB1 isn't confined to the brain. Subsequent research found it throughout the body:
- Gut — the enteric nervous system and intestinal mucosa, regulating motility and secretion
- Liver — low normally but dramatically upregulated in disease, contributing to insulin resistance and fibrosis
- Heart and blood vessels — upregulated in cardiovascular disease
- Peripheral nerves — dorsal root ganglia, trigeminal ganglion, regulating pain signaling
- Fat tissue — involved in metabolic regulation
- Immune cells — present on some white blood cells
Even within neurons, CB1 isn't limited to the cell surface. It's been found on mitochondria — the cell's energy factories — where it directly regulates cellular respiration. The receptor is as fundamental as it is ubiquitous.
CB1 and CB2 — Siblings, Not Twins
Three years after CB1 was cloned, Sean Munro at the MRC Laboratory of Molecular Biology in Cambridge identified a second cannabinoid receptor from an immune cell library.
CB1 (CNR1)
- 472 amino acids (human)
- Cloned 1990 (Matsuda, NIMH)
- Most abundant GPCR in the brain
- Dense in hippocampus, cerebellum, basal ganglia, cortex
- Also in gut, liver, heart, peripheral nerves
- Mediates the psychoactive effects of THC
- Primary target for tolerance and withdrawal
The brain receptor
CB2 (CNR2)
- 360 amino acids (human)
- Cloned 1993 (Munro, Cambridge)
- Only 44% amino acid homology with CB1
- Primarily in immune cells (spleen, tonsils, white blood cells)
- Low but detectable in brain (microglia, reward regions)
- Non-psychoactive when activated
- Involved in inflammation and immune regulation
The immune receptor
Matsuda et al. (1990), Nature; Munro et al. (1993), Nature; Zou & Kumar (2018)
The two receptors share less than half their amino acid sequence, evolved to serve different physiological roles, and are expressed in largely different tissue types. But both bind THC and endocannabinoids, and both belong to the GPCR superfamily. Together they form the receptor foundation of the endocannabinoid system.
What Knowing the Gene Made Possible
Cloning CB1 didn't just identify a protein. It handed researchers a toolkit: the ability to make knockout mice, design selective drugs, map the receptor's structure at atomic resolution, and understand exactly how cannabis interacts with the brain.
Research Timeline
From Gene to Drugs to Cautionary Tales
Howlett & Devane prove cannabinoid binding sites exist in brain
The pharmacological evidence — stereoselective, saturable, Gi-coupled
Herkenham maps binding site distribution by autoradiography
The shadow of the receptor — dense in hippocampus, cerebellum, basal ganglia
Matsuda et al. clone the CB1 receptor gene
The molecular identity — 472 amino acids, 7 transmembrane domains, most abundant GPCR in brain
Anandamide discovered (Devane, Hanuš, Mechoulam)
The brain's own CB1 ligand — answering 'why does this receptor exist?'
CB2 receptor cloned (Munro, Cambridge)
A second cannabinoid receptor, primarily in immune cells
SR141716A (rimonabant) announced as first selective CB1 antagonist
The first drug designed to block CB1 specifically
CB1 knockout mice created (Zimmer; Ledent)
Confirmed CB1 mediates THC's behavioral effects — knockouts are unresponsive to cannabis
Rimonabant approved in Europe for obesity
CB1 blockade worked for weight loss — but at a cost
Rimonabant withdrawn due to psychiatric side effects
Depression, anxiety, suicidality — CB1 is too fundamental to simply block
CB1 crystal structure solved (Hua et al.)
Atomic-resolution structure enables precision drug design
Pertwee (2006), Br J Pharmacol; Zou & Kumar (2018), PMC5877694
The Cautionary Tale of Rimonabant
Once you know a receptor's gene, you can design drugs against it. The pharmaceutical industry did exactly that — and the result was both a triumph and a disaster.
The Promise
strong- CB1 activation stimulates appetite — blocking it should reduce appetite and cause weight loss
- Rimonabant (SR141716A) produced significant weight loss in clinical trials
- Also improved metabolic markers: insulin sensitivity, HDL cholesterol, triglycerides
- Approved by European Medicines Agency in 2006 for obesity
The Problem
strong- CB1 receptors regulate mood, reward, and stress — not just appetite
- Post-marketing reports: depression, anxiety, insomnia, suicidal ideation
- Psychiatric adverse events occurred in a significant minority of patients
- FDA issued a non-approvable letter for the US market
- European approval withdrawn in 2008; Sanofi retracted its application
Rimonabant proved that CB1 is a viable drug target for metabolic disease — but also that it is so deeply wired into mood and reward circuitry that systemically blocking it is dangerous. Current research focuses on peripherally-restricted CB1 antagonists (that don't enter the brain), allosteric modulators (that fine-tune rather than block the receptor), and FAAH inhibitors (that boost endocannabinoids rather than directly targeting CB1).
EMA withdrawal (2008); Zou & Kumar (2018), PMC5877694
The lesson was profound. CB1 is not a peripheral metabolic switch you can flip without consequences. It's woven into the brain's fundamental architecture for processing reward, regulating mood, and managing stress. You can't simply turn it off.
Why This Matters for Cannabis Users
Understanding CB1 biology explains three things that every cannabis user experiences:
Tolerance: When THC floods CB1 receptors chronically, the brain responds by pulling receptors off the cell surface (internalization) and reducing their sensitivity (desensitization). Fewer functional CB1 receptors means you need more THC for the same effect.
Withdrawal: When you stop using cannabis, your brain has fewer CB1 receptors than normal — and the endocannabinoid system those receptors serve is temporarily impaired. This is why withdrawal produces anxiety, insomnia, irritability, and appetite loss — all functions CB1 regulates.
Recovery: CB1 receptors recover. Imaging studies show that receptor density returns to normal levels within approximately 2-4 weeks of abstinence. This is the biological basis for tolerance breaks — you're not just "resetting" subjectively, you're allowing your CB1 receptors to come back to the cell surface.
The receptor Matsuda's team cloned in 1990 is the same receptor your brain is adjusting every time you use cannabis. Knowing its gene made it possible to understand — at the molecular level — exactly what chronic use does and why recovery works.
Related Research
The Studies That Led Here — and Those That Followed
CB1 sits at the center of cannabinoid science. Its cloning connected the pharmacology that preceded it to the endocannabinoid biology that followed.
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni & Mechoulam (1964)
The molecule CB1 was built to respond to (via its endogenous ligands) — and that THC mimics
Isolation and structure of a brain constituent that binds to the cannabinoid receptor
Devane, Hanuš, Mechoulam et al. (1992)
The endogenous ligand for CB1 — discovered because the receptor demanded an explanation
Molecular characterization of CB2 receptor
Munro et al. (1993)
The sibling receptor — 44% homology, primarily in immune cells
Gi signaling in cannabinoid responses
Howlett et al. (1986)
Signaling evidence cited as reference 6 in the original Matsuda cloning paper
What is the CB1 receptor and why does it matter?
CB1 is a protein on the surface of brain cells — and cells throughout the body — that THC binds to produce its effects. It is the most abundant G-protein-coupled receptor in the mammalian brain, more common than receptors for serotonin, dopamine, or endorphins. Its extraordinary abundance in regions governing memory (hippocampus), coordination (cerebellum), mood (cortex/amygdala), and appetite (hypothalamus) explains why cannabis affects so many different functions simultaneously.
Is CB1 the same as the endocannabinoid system?
CB1 is one component of the endocannabinoid system — the receptor that detects the signal. The full system includes two receptors (CB1 and CB2), at least two endogenous signaling molecules (anandamide and 2-AG), and the enzymes that produce and break down those molecules (NAPE-PLD, DAGL, FAAH, MAGL). CB1 was the first component identified at the molecular level, and its discovery in 1990 led directly to the identification of all the others.
What the researchers found
A complementary DNA (cDNA) encoding a G protein-coupled receptor (GPCR) was cloned from a rat brain library. When expressed in cultured cells, the receptor inhibited adenylate cyclase activity in a dose-dependent, stereoselective, and pertussis toxin-sensitive manner — all hallmarks of cannabinoid receptor pharmacology. The receptor responded preferentially to psychoactive cannabinoids while showing minimal response to non-psychoactive cannabinoids. In situ hybridization revealed that the receptor's mRNA was localized to brain regions and cell lines previously shown to contain cannabinoid binding sites by autoradiography. The receptor protein consists of 472 amino acids (human) with seven transmembrane domains characteristic of GPCRs, and shows 97-99% amino acid identity across mammalian species.
Why it matters
This paper provided the molecular identity of the cannabinoid receptor, transforming cannabinoid research from pharmacology into molecular biology. Knowing the gene sequence enabled everything that followed: creation of knockout mice, development of selective antagonists, identification of the endogenous ligands (anandamide and 2-AG), and the eventual development of cannabinoid-based therapeutics. It also revealed that CB1 is the most abundant GPCR in the mammalian brain — a finding that explained why cannabis has such widespread effects on cognition, mood, pain, appetite, coordination, and memory.
How the study worked
The researchers screened a rat brain complementary DNA (cDNA) library for sequences homologous to known G-protein-coupled receptors. A clone encoding a novel GPCR was identified, sequenced, and expressed in cultured cells (transfection). The expressed receptor was then tested pharmacologically: its ability to inhibit adenylate cyclase was measured in the presence of various cannabinoid compounds at different concentrations. Stereoselective binding was confirmed by testing enantiomeric pairs of cannabinoids. Pertussis toxin sensitivity confirmed Gi/o protein coupling. In situ hybridization was used to map where the receptor's messenger RNA was expressed in rat brain sections, and the resulting distribution was compared to known cannabinoid binding site maps from autoradiography studies.
What this study cannot tell us
This was a molecular cloning and in vitro characterization study. The receptor was expressed in cultured cells, not studied in intact animals or humans. No in vivo behavioral data were presented. The initial paper characterized the rat receptor; the human CB1 gene was cloned subsequently by Gérard and colleagues in Brussels. The study did not address receptor distribution in peripheral tissues or non-neuronal cells, which were later found to be significant.
How to read the evidence
Rated strong because this is a definitive molecular biology result. The receptor gene has been independently cloned, sequenced, and characterized in multiple species. Its identity as the primary mediator of THC's psychoactive effects has been confirmed by thousands of subsequent studies including knockout mouse experiments.
When this study was published
Published in 1990, this 36-year-old paper established the molecular identity of the cannabinoid receptor. The gene sequence, receptor characterization, and brain distribution findings have been confirmed and expanded by hundreds of subsequent studies. CB1 remains the primary target of cannabinoid pharmacology.
The bigger picture
The cloning of CB1 was the molecular foundation for the endocannabinoid system. It made possible the discovery of anandamide (1992), the creation of CB1 knockout mice (1999), the development of rimonabant (a CB1 antagonist for obesity — approved in Europe 2006, withdrawn 2008 due to psychiatric side effects), and the 2016 determination of CB1's crystal structure. The receptor's extraordinary abundance in the brain — denser than serotonin, dopamine, or opioid receptors — explained a longstanding puzzle: why does cannabis affect so many different brain functions? Because its receptor is everywhere.
Questions still open
- If the brain has dedicated receptors for cannabinoids, does the body produce its own cannabinoid-like molecules?
- Are there other cannabinoid receptors beyond this one?
- Why is this receptor so abundant — what essential function does it serve?
Common questions
What is the CB1 receptor and why does it matter?
Is CB1 the same as the endocannabinoid system?
Read the original research
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Nature, 346(6284), 561-564
Citation
Matsuda, L A; Lolait, S J; Brownstein, M J; Young, A C; Bonner, T I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346(6284), 561-564. https://doi.org/10.1038/346561a0